Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life
المؤلفون المشاركون
Mortensen, P. B.
Gottschalck, I. B.
Poulsen, Steen Seier
Holst, Jens Juul
Jeppesen, P. B.
Nielsen, H. B.
Quistorff, B.
Mortensen, J.
Lund, P.
المصدر
Gastroenterology Research and Practice
العدد
المجلد 2009، العدد 2009 (31 ديسمبر/كانون الأول 2009)، ص ص. 1-9، 9ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2009-07-05
دولة النشر
مصر
عدد الصفحات
9
التخصصات الرئيسية
الملخص EN
Background and aims.
Glucagon-like peptide 2 (GLP-2) has been shown to improve intestinal absorption in short bowel syndrome (SBS) patients in a short-term study.
This study describes safety, compliance, and changes in quality of life in 11 SBS patients at baseline, week 13, 26, and 52 during two years of subcutaneous GLP-2 treatment, 400 microgram TID, intermitted by an 8-week washout period.
Methods.
Safety and compliance was evaluated during the admissions.
The Sickness Impact Profile (SIP), Short Form 36 (SF 36), and Inflammatory Bowel Disease Questionnaire (IBDQ) evaluated quality of life.
Results.
The predominant adverse event was transient abdominal discomfort in 5 of 11 patients, but in 2, both suffering from Crohns disease, it progressed to abdominal pain and led to discontinuation of GLP-2 treatment.
One had a fibrostenotic lesion electively resected at the jejuno-ascendo-anastomosis.
The investigator excluded a patient due to unreliable feedback.
Stoma nipple enlargement was seen in all 9 jejunostomy patients.
Reported GLP-2 compliance was excellent (>93%).
GLP-2 improved the overall quality of life VAS-score (4.1±2.8 cm versus 6.0±2.4 cm, P<.01), the overall SIP score (10.3±8.9% versus 6.2±9.5%, P<.001), the mental component of the SF-36 (45±13% versus 53±11%, P<.05), and the overall IBDQ score (5.1±0.9 versus 5.4±0.9, P<.007) in the 8 patients completing the study.
Conclusions.
Long-term treatment with GLP-2 is feasible in SBS patients, although caution must be exercised in patients with a history of abdominal pain.
Although conclusions cannot be made in a noncontrolled trial, the high reported compliance might reflect a high treatment satisfaction, where the clinical benefits of GLP-2 may outweigh the discomforts of injections.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Jeppesen, P. B.& Lund, P.& Gottschalck, I. B.& Nielsen, H. B.& Holst, Jens Juul& Mortensen, J.…[et al.]. 2009. Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life. Gastroenterology Research and Practice،Vol. 2009, no. 2009, pp.1-9.
https://search.emarefa.net/detail/BIM-471206
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Jeppesen, P. B.…[et al.]. Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life. Gastroenterology Research and Practice No. 2009 (2009), pp.1-9.
https://search.emarefa.net/detail/BIM-471206
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Jeppesen, P. B.& Lund, P.& Gottschalck, I. B.& Nielsen, H. B.& Holst, Jens Juul& Mortensen, J.…[et al.]. Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2 (GLP-2) : Compliance, Safety, and Effects on Quality of Life. Gastroenterology Research and Practice. 2009. Vol. 2009, no. 2009, pp.1-9.
https://search.emarefa.net/detail/BIM-471206
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-471206
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر